{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:52:08Z","timestamp":1777726328535,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Our meta-analysis was undertaken to evaluate the efficacy and safety of nebivolol compared with other second-generation \u03b2 blockers for hypertensive patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, the Cochrane Library, EMBASE, and Clinical Trials.gov databases for randomized controlled trials (RCTs). The efficacy endpoints included systolic blood pressure (SBP), diastolic blood pressure (DBP), reduction of SBP and DBP, heart rate (HR), and adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Eight RCTs with 1514 patients met the inclusion criteria. HR was significantly lower in patients receiving other second-generation \u03b2 blockers compared with patients receiving nebivolol. There was no difference the reduction of blood pressure (SBP and DBP) or the reduction of SBP or DBP between the groups. The incidence of AEs was lower in patients taking nebivolol compared with patients taking other second-generation \u03b2 blockers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No significant difference was demonstrated between nebivolol and other second-generation \u03b2 blockers in the reduction of blood pressure, SBP, and DBP. The tolerability of nebivolol was significantly better compared with other second-generation \u03b2 blockers, and nebivolol was also associated with a stable HR and a lower risk of AEs compared with other second-generation \u03b2 blockers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0300060520931625","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:53:25Z","timestamp":1603241605000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of nebivolol in hypertensive patients: a meta-analysis of randomized controlled trials"],"prefix":"10.1177","volume":"48","author":[{"given":"Jun-Ying","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Na","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Plastic and Cosmetic Medicine, Cangzhou Central Hospital, Cangzhou, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Zhong","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Min","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8781-6656","authenticated-orcid":false,"given":"Ze-Sheng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.5603\/KP.2019.0018"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.351"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/08037050701461084"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000107251.49515.c2"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.6.677"},{"key":"e_1_3_4_7_2","unstructured":"http: \/\/prisma-statement.org\/documents\/PRISMA%202009%20flow%20diagram.pdf"},{"key":"e_1_3_4_8_2","first-page":"HC01","article-title":"Beneficial effects of nebivolol in comparison with atenolol on safety and tolerability in essential hypertension","volume":"8","author":"Bhosale VV","year":"2014","unstructured":"Bhosale VV, Inamdar SC, Karande VB, et al. Beneficial effects of nebivolol in comparison with atenolol on safety and tolerability in essential hypertension. J Clin Diagn Res 2014; 8: HC01\u2013HC04.","journal-title":"J Clin Diagn Res"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200525060-00006"},{"key":"e_1_3_4_10_2","first-page":"728","article-title":"Comparison on the efficiency of nebivolol and atenolol in the primary hypertensive patients","volume":"33","author":"Chenmin Q","year":"2013","unstructured":"Chenmin Q, Qingyuan Z, Xiaohong G. Comparison on the efficiency of nebivolol and atenolol in the primary hypertensive patients. Chinese Journal of Hospital Pharmacy 2013; 33: 728\u2013730.","journal-title":"Chinese Journal of Hospital Pharmacy"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026180325278"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/08038020310023271"},{"key":"e_1_3_4_13_2","first-page":"83","article-title":"The efficacy and safety of nebivolol tablet in mild to moderate essential hypertensive patients","volume":"29","author":"Shan J","year":"2013","unstructured":"Shan J, Yuanyuan C, Ningling S, et al. The efficacy and safety of nebivolol tablet in mild to moderate essential hypertensive patients. The Chinese Journal of Clinical Pharmacology 2013; 29: 83\u201385.","journal-title":"The Chinese Journal of Clinical Pharmacology"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/608683"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666100-00007"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)10549-1"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200112003-00003"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00129784-200808010-00005"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300060520931625","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0300060520931625","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300060520931625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:46:04Z","timestamp":1777459564000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0300060520931625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1177\/0300060520931625"],"URL":"https:\/\/doi.org\/10.1177\/0300060520931625","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]},"article-number":"0300060520931625"}}